SINGAPORE, July 12, 2016 /CNW/ - Zecotek Photonics
Inc. (TSX-V: ZMS; Frankfurt:
W1I.F, OTCPK: ZMSPF), a developer of leading-edge
photonics technologies for industrial, healthcare and scientific
markets, is pleased to announce that the University of California at Davis has order
additional patented LFS scintillation crystals for a leading edge
approach to positron emission tomography (PET) scanning which
combines PET and magnetic resonance (MR) into a single PET/MR
module.
"Once again we have turned to Zecotek Photonics to supply high
quality LFS scintillation crystals for our new approaches to PET
detectors," said Dr. Simon R.
Cherry, Distinguished Professor, Department of Biomedical
Engineering, University of California,
Davis. "This experiment combines positron emission
tomography with magnetic resonance in a module to produce a more
effective scanning device in specific situations. Zecotek's
scintillation crystals have unique qualities including fast decay
time that make them attractive for a range of high-performance PET
detector designs."
"The University of California, Davis
has ordered additional LFS-3 scintillation crystals for an upcoming
experiment for high resolution PET detectors," said Dr.
A.F. Zerrouk, Chairman, President,
and CEO of Zecotek Photonics Inc. "We continue to maintain a close
relationship with Cherry Labs and UC
Davis, who have experienced firsthand the benefits of LFS crystals
from both a cost and performance perspective. Our fast decay times
and high light yield combined with competitive pricing make them
the ideal choice for PET development and manufacturing both at a
research and industrial level. Cherry
Labs continues to be a leader in the nuclear medicine
research field and we are proud to support them in their
endeavors."
As previously announced in September
2015, the University of California,
Davis successfully tested the patented LFS scintillation
crystals in a new leading edge coating-based, depth-encoding
approach for PET detectors. This order of additional LFS crystals
is for PET/MR modules.
While it is not expect that combined PET/MR will replace PET/CT
for clinical diagnostics, it is likely to overtake PET/CT in
small-animal and clinical research. PET/MR presents advantages
because MR does not require additional ionizing radiation like CT
does, and it provides much better soft-tissue contrast. MR's low
sensitivity is combined with PET's high sensitivity, and MR makes
up for PET's lack of anatomic landmarks for metabolic
information.
Another advantage of combined PET/MR is the acquiring of
multiple functional and physiologic parameters at the same time,
such as temperature, blood pressure, and heart rate. This can be
especially important when imaging certain parts of the body, such
as the abdominal area, where differences in patient movement and
position makes fusing sequential images problematic.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS;
Frankfurt: W1I) is a photonics technology company developing
high-performance scintillation crystals, photo detectors, positron
emission tomography scanning technologies, 3D auto-stereoscopic
displays, 3D metal printing, and lasers for applications in
medical, high-tech and industrial sectors. Founded in 2004,
Zecotek operates three divisions: Imaging Systems, Optronics
Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on
building shareholder value by commercializing over 50 patented and
patent pending novel photonic technologies directly and through
strategic alliances, the European Organization for Nuclear Research
(Switzerland), Beijing
Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center
(South Korea). For more
information visit www.zecotek.com and follow @zecotek on
Twitter.
This press release may contain forward-looking statements
that are based on management's expectations, estimates, projections
and assumptions. These statements are not guarantees of future
performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends
may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of the content of this news release. If you would like to
receive news from Zecotek in the future please visit the corporate
website at www.zecotek.com.
SOURCE Zecotek Photonics Inc.